노인에서 항콜린성 약물의 사용

참고문헌 (81)

1. Potamianos G, "Anti-cholinergic drugs and memory : the effects of benzhexol on memory in a group of geriatric patients", Br J Psychiatry, 140, pp.470~472 (1982)
2. American Geriatrics Society 2012 Beers Criteria Update Expert Panel, "American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults", J Am Geriatr Soc, 60, pp.616~631 (2012)
3. O’Mahony D, "STOPP", START criteria for potentially inappropriate prescribing in older people : version 2, 2015, pp.44, 213~218
4. 남진선, "한국의 외래노인환자에서 약물사용의 경향 및 explicit criteria에 의한 적절성평가", 한국임상약학회지, 15(2), pp.149~159 (2005), 한국임상약학회
5. 이준석, "일개 노인복지관 방문 노인환자들의 다약제복용과 부적절한 약물처방 실태", Korean Journal of Family Medicine, 29(12), pp.925~931 (2008), 대한가정의학회
6. Sathienluckana T, "Anticholinergic discontinuation and cognitive functions in patients with schizophrenia : a pharmacist-physician collaboration in the outpatient department", Integr Pharm Res Pract, 7, pp.161~171 (2018)
7. Bishara D, "Anticholinergic effect on cognition(AEC)of drugs commonly used in older people", Int J Geriatr Psychiatry, 32, pp.650~656 (2017)
8. Perry EK, "Increased Alzheimer pathology in Parkinson’s disease related to antimuscarinic drugs", Ann Neurol, 54, pp.235~238 (2003)
9. Caccamo A, "M1 receptors play a central role in modulating ADlike pathology in transgenic mice", Neuron, 49, pp.671~682 (2006)
10. Risacher SL, "Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults", JAMA Neurol, 73, pp.721~732 (2016)
11. Chuang YF, "Midlife anticholinergic drug use, risk of Alzheimer’s disease, and brain atrophy in community-dwelling older adults", Alzheimers Dement(NY), 3, pp.471~479 (2017)
12. Kitajima Y, "A review of the role of anticholinergic activity in Lewy body disease and delirium", Neurodegener Dis, 15, pp.162~167 (2015)
13. Konishi K, "Hypothesis of endogenous anticholinergic activity in Alzheimer’s disease", Neurodegener Dis, 15, pp.149~156 (2015)
14. Lemstra AW, "The cholinergic deficiency syndrome and its therapeutic implications", Gerontology, 49, pp.55~60 (2003)
15. Lai MK, "Psychosis of Alzheimer’s disease is associated with elevated muscarinic M2 binding in the cortex", Neurology, 57, pp.805~811 (2001)
16. Gorup E, "Anticholinergic burden and most common anticholinergic-acting medicines in older general practice patients", Zdr varst, 57, pp.140~147 (2018)
17. Grande G, "Role of anticholinergic burden in primary care patients with first cognitive complaints", Eur J Neurol, 24, pp.950~955 (2017)
18. Kachru N, "Potentially inappropriate anticholinergic medication use in older adults with dementia", J Am Pharm Assoc, 55, pp.603~612 (2015)
19. Niznik J, "Anticholinergic prescribing in medicare part D beneficiaries residing in nursing homes : results from a retrospective cross-sectional analysis of medicare data", Drugs Aging, 34, pp.925~939 (2017)
20. Brombo G, "Association of anticholinergic drug burden with cognitive and functional decline over time in older inpatients : results from the CRIME project", Drugs Aging, 35, pp.917~924 (2018)
21. Wu YH, "Association between using medications with anticholinergic properties and short-term cognitive decline among older men : a retrospective cohort study in Taiwan", Geriatr & Gerontol Int, 17, pp.57~64 (2017)
22. Green AR, "Anticholinergic burden in older adults with mild cognitive impairment", J Am Geriatr Soc, 64, pp.e313~e314 (2016)
23. Cross AJ, "Potentially inappropriate medications and anticholinergic burden in older people attending memory clinics in Australia", Drugs Aging, 33, pp.37~44 (2016)
24. Lee EK, "Prescription patterns of anticholinergic agents and their associated factors in Korean elderly patients with dementia", Int J Clin Pharm, 35, pp.711~718 (2013)
25. López-Álvarez J, "STOPP", START criteria and psycho-geriatric practice, 2019, pp.54, 61~
26. Bala SS, "Determinants of prescribing potentially i nappropriate medications i n a nationwide cohort of community dwellers with dementia receiving a comprehensive geriatric assessment", Int J Geriatr Psychiatry, 34, pp.153~161 (2019)
27. Tune L, "Serum levels of anticholinergic drugs in treatment of acute extrapyramidal side effects", Arch Gen Psychiatry, 37, pp.293~297 (1980)
28. Flacker JM, "Serum anticholinergic activity changes with acute illness in elderly medical patients", J Gerontol A Biol Sci Med Sci, 54, pp.M12~M16 (1999)
29. Plaschke K, "Increased cortisol levels and anticholinergic activity in cognitively unimpaired patients", J Neuropsychiatry Clin Neurosci, 22, pp.433~441 (2010)
30. Collamati A, "Anticholinergic drugs and negative outcomes in the older population : from biological plausibility to clinical evidence", Aging Clin Exp Res, 28, pp.25~35 (2016)
31. Mayer T, "Limitations of the anticholinergic activity assay and assay-based anticholinergic drug scales", Am J Geriatr Psychiatry, 24, pp.1182~1188 (2016)
32. Plaschke K, "The impact of plasma cholinergic enzyme activity and other risk factors for the development of delirium in patients receiving palliative care", J Pain Symptom Manage, 52, pp.525~532 (2016)
33. Carnahan RM, "The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden : associations with serum anticholinergic activity", J Clin Pharmacol, 46, pp.1481~1486 (2006)
34. Rudolph JL, "The Anticholinergic Risk Scale and anticholinergic adverse effects in older persons", Arch Intern Med, 168, pp.508~513 (2008)
35. Boustani M, "Impact of anticholinergics on the aging brain : a review and practical application", Aging Health, 4, pp.311~320 (2008)
36. Hilmer SN, "A drug burden index to define the functional burden of medications in older people", Arch Intern Med, 167, pp.781~787 (2007)
37. Ancelin ML, "Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs : longitudinal cohort study", BMJ, 332, pp.455~459 (2006)
38. Ehrt U, "Use of drugs with anticholinergic effect and impact on cognition in Parkinson’s disease : a cohort study", J Neurol Neurosurg Psychiatry, 81, pp.160~165 (2010)
39. Sittironnarit G, "Effects of anticholinergic drugs on cognitive function in older Australians : results from the AIBL study", Dement Geriatr Cogn Disord, 31, pp.173~178 (2011)
40. Briet J, "The anticholinergic impregnation scale : towards the elaboration of a scale adapted to prescriptions in French psychiatric settings", Therapie, 72, pp.427~437 (2017)
41. Salahudeen MS, "Examination and estimation of anticholinergic burden : current trends and implications for future research", Drugs Aging, 33, pp.305~313 (2016)
42. Crow TJ, "An analysis of the learning deficit following hyoscine administration to man", Br J Pharmacol, 49, pp.322~327 (1973)
43. Ziad A, "Anticholinergic drug use and cognitive performances in middle age : findings from the CONSTANCES cohort", J Neurol Neurosurg Psychiatry, 89, pp.1107~1115 (2018)
44. Lechevallier-Michel N, "Drugs with anticholinergic properties and cognitive performance in the elderly : results from the PAQUID study", Br J Clin Pharmacol, 59, pp.143~151 (2005)
45. Fortin MP, "Effects of anticholinergic drugs on verbal episodic memory function in the elderly: a retrospective, cross-sectional study", Drugs Aging, 28, pp.195~204 (2011)
46. Cai X, "Long-term anticholinergic use and the aging brain", Alzheimers Dement, 9, pp.377~385 (2013)
47. Campbell NL, "Anticholinergics influence transition from normal cognition to mild cognitive impairment in older adults in primary care", Pharmacotherapy, 38, pp.511~519 (2018)
48. Richardson K, "Anticholinergic drugs and risk of dementia : case-control study", BMJ, 361, pp.k1315~ (2018)
49. Jessen F, "Anticholinergic drug use and risk for dementia : target for dementia prevention", Eur Arch Psychiatry Clin Neurosci, 260, pp.111~115 (2010)
50. Gray SL, "Cumulative use of strong anticholinergics and incident dementia : a prospective cohort study", JAMA intern Med, 175, pp.401~407 (2015)
51. Fox C, "Anticholinergic medication use and cognitive impairment in the older population : the medical research council cognitive function and ageing study", J Am Geriatr Soc, 59, pp.1477~1483 (2011)
52. Chase TN, "Donepezil plus solifenacin(CPC-201)treatment for Alzheimer’s disease", Neurotherapeutics, 14, pp.405~416 (2017)
53. Egberts A, "Anticholinergic drug exposure is associated with delirium and postdischarge institutionalization in acutely ill hospitalized older patients", Pharmacol Res Perspect, 5, pp.e00310~ (2017)
54. Cancelli I, "Drugs with anticholinergic properties as a risk factor for psychosis in patients affected by Alzheimer’s disease", Clin Pharmacol Ther, 84, pp.63~68 (2008)
55. Hori K, "Influence of anticholinergic activity in serum on clinical symptoms of Alzheimer’s disease", Neuropsychobiology, 63, pp.147~153 (2011)
56. Dauphinot V, "Anticholinergic drugs and functional, cognitive impairment and behavioral disturbances in patients from a memory clinic with subjective cognitive decline or neurocognitive disorders", Alzheimers Res Ther, 9, pp.58~ (2017)
57. Cancelli I, "Factors associated with complex visual hallucinations during antidepressant treatment", Hum Psychopharmacol, 19, pp.577~584 (2004)
58. Bostock CV, "Associations between different measures of anticholinergic drug exposure and Barthel Index in older hospitalized patients", Ther Adv Drug Saf, 20134, pp.235~245
59. Sanders LMJ, "Relationship between drug burden and physical and cognitive functions in a sample of nursing home patients with dementia", Eur J Clin Pharmacol, 73, pp.1633~1642 (2017)
60. Mayer T, "Comparison of nine instruments to calculate anticholinergic load in a large cohort of older outpatients: association with cognitive and functional decline, falls, and use of Laxatives", Am J Geriatr Psychiatry, 25, pp.531~540 (2017)
61. Wouters H, "Quantification of anticholinergic and sedative drug load with the Drug Burden Index : a review of outcomes and methodological quality of studies", Eur J Clin Pharmacol, 73, pp.257~266 (2017)
62. Lowry E, "Associations between the anticholinergic risk scale score and physical function : potential implications for adverse outcomes in older hospitalized patients", J Am Med Dir Assoc, 12, pp.565~572 (2011)
63. Kröger E, "Is the drug burden index related to declining functional status at follow-up in community-dwelling seniors consulting for minor injuries? Results from the Canadian emergency team initiative cohort study", Drugs Aging, 36, pp.73~83 (2019)
64. Kose E, "Anticholinergic load negatively correlates with recovery of cognitive activities of daily living for geriatric patients after stroke in the convalescent stage", J Clin Pharm Ther, 43, pp.799~806 (2018)
65. Cossette B, "Association between anticholinergic drug use and health-related quality of life in community-dwelling older adults", Drugs Aging, 34, pp.785~792 (2017)
66. Teramura-Grönblad M, "Use of anticholinergic drugs and cholinesterase inhibitors and their association with psychological well-being among frail older adults in residential care facilities", Ann Pharmacother, 45, pp.596~602 (2011)
67. Zia A, "Anticholinergic burden is associated with recurrent and injurious falls in older individuals", Maturitas, 84, pp.32~37 (2016)
68. Marcum ZA, "Anticholinergic use and recurrent falls in community-dwelling older adults : findings from the health ABC study", Ann Pharmacother, 49, pp.1214~1221 (2015)
69. Vetrano DL, "Anticholinergic medication burden and 5-year risk of hospitalization and death in nursing home elderly residents with coronary artery disease", J Am Med Dir Assoc, 17, pp.1056~1059 (2016)
70. Campbell NL, "Association of anticholinergic burden with cognitive impairment and health care utilization among a diverse ambulatory older adult population", Pharmacotherapy, 36, pp.1123~1131 (2016)
71. Lattanzio F, "Anticholinergic burden and 1-year mortality among older patients discharged from acute care hospital", Geriatr Gerontol Int, 18, pp.705~713 (2018)
72. Mangoni AA, "Measures of anticholinergic drug exposure, serum anticholinergic activity, and all-cause postdischarge mortality in older hospitalized patients with hip fractures", Am J Geriatr Psychiatry, 21, pp.785~793 (2013)
73. Tan ECK, "Anticholinergic burden and risk of stroke and death in people with different types of dementia", J Alzheimers Dis, 65, pp.589~596 (2018)
74. Lupu AM, "Reducing anticholinergic medication burden in patients with psychotic or bipolar disorders", J Clin Psychiatry, 78, pp.e1270~e1275 (2017)
75. Salahudeen MS, "Impact of anticholinergic discontinuation on cognitive outcomes in older people : a systematic review", Drugs Aging, 31, pp.185~192 (2014)
76. Kersten H, "Cognitive effects of reducing anticholinergic drug burden in a frail elderly population : a randomized controlled trial", J Gerontol A Biol Sci Med Sci, 68, pp.271~278 (2013)
77. Chew ML, "Anticholinergic activity of 107 medications commonly used by older adults", J Am Geriatr Soc, 56, pp.1333~1341 (2008)
78. Nishiyama K, "Reversible memory disturbance and intelligence impairment induced by long-term anticholinergic therapy", Intern Med, 37, pp.514~518 (1998)
79. Pasina L, "Relation between delirium and anticholinergic drug burden in a cohort of hospitalized older patients : an observational study", Drugs Aging, 36, pp.85~91 (2019)
80. Araklitis G, "Anticholinergic prescription: are healthcare professionals the real burden?", Int Urogynecol J, 28, pp.1249~1256 (2017)
81. Sverdrup Efjestad A, "Comedication and treatment length in users of acetylcholinesterase inhibitors", Dement Geriatr Cogn Dis Extra, 7, pp.30~40 (2017)

관련 논문AI추천